Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Research ArticleContinuing Education

Amyloid Imaging Update: How the Amyloid Landscape Is Changing in Light of the Recent Food and Drug Administration Approval of Antiamyloid Therapeutics

Barbara J. Grabher
Journal of Nuclear Medicine Technology December 2024, 52 (4) 314-325; DOI: https://doi.org/10.2967/jnmt.124.268329
Barbara J. Grabher
Grabher Consulting & Specialty Services, Forest Hill, Maryland
CNMT, RT(N), NCT FSNMMI-TS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Errata - March 01, 2025

Visual Abstract

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

It has been some time since the Journal of Nuclear Medicine and Technology has published an article on best practices in amyloid imaging. In light of the recent Food and Drug Administration approval of new antiamyloid therapies (AATs) to decrease amyloid plaques in the brain and slow progression of mild cognitive impairment, and the potential increase in the number of amyloid PET scans being acquired to document amyloid plaques, the Journal of Nuclear Medicine and Technology felt it was a perfect time to publish a refresher on best practices. AATs are administered to help slow progression of mild cognitive impairment, allowing patients to live independently a little longer before having to give up their independence and move in with family or into an assisted living facility. Neurologists prescribing AATs must first document that the patient has amyloid plaques. To do this, amyloid PET can be performed, or a lumbar puncture can be used to look for amyloid plaques in the cerebrospinal fluid. Although the latter is more cost-effective and has no associated radiation exposure, it is highly invasive compared with amyloid PET. High-quality amyloid PET scans interpretated by a trained nuclear medicine physician are the first step and key to providing the dementia expert and patient with accurate information on amyloid status, allowing for the best decisions on patient management.

  • amyloid imaging
  • PET
  • antiamyloid therapeutics
  • quantification
  • reimbursement

Footnotes

  • CE credit: For CE credit, you can access the test for this article, as well as additional JNMT CE tests, online at https://www.snmmilearningcenter.org. Complete the test online no later than December 2027. Your online test will be scored immediately. You may make 3 attempts to pass the test and must answer 80% of the questions correctly to receive 2.0 CEH (Continuing Education Hour) credit. SNMMI members will have their CEH credit added to their VOICE transcript automatically; nonmembers will be able to print out a CE certificate upon successfully completing the test. The online test is free to SNMMI members; nonmembers must pay $15.00 by credit card when logging onto the website to take the test.

  • Published online Nov. 12, 2024.

View Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 52 (4)
Journal of Nuclear Medicine Technology
Vol. 52, Issue 4
December 1, 2024
  • Table of Contents
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Amyloid Imaging Update: How the Amyloid Landscape Is Changing in Light of the Recent Food and Drug Administration Approval of Antiamyloid Therapeutics
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Amyloid Imaging Update: How the Amyloid Landscape Is Changing in Light of the Recent Food and Drug Administration Approval of Antiamyloid Therapeutics
Barbara J. Grabher
Journal of Nuclear Medicine Technology Dec 2024, 52 (4) 314-325; DOI: 10.2967/jnmt.124.268329

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Amyloid Imaging Update: How the Amyloid Landscape Is Changing in Light of the Recent Food and Drug Administration Approval of Antiamyloid Therapeutics
Barbara J. Grabher
Journal of Nuclear Medicine Technology Dec 2024, 52 (4) 314-325; DOI: 10.2967/jnmt.124.268329
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MECHANISM OF ACTION, PHARMACODYNAMICS, AND PHARMACOKINETICS
    • APPROPRIATE USE CRITERIA (AUC) FOR AMYLOID PET
    • CLINICAL INDICATION AND LIMITATIONS OF USE
    • PATIENT PREPARATION
    • DOSE AND ADMINISTRATION
    • ACQUISITION AND PROCESSING
    • TRACER DISTRIBUTION PATTERNS
    • IMAGE INTERPRETATION
    • WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS
    • USE IN SPECIAL PATIENT POPULATIONS
    • AQ AND CENTILOIDS
    • BENEFITS AND LIMITATIONS OF AMYLOID PET
    • MARKET ACCESS AND REIMBURSEMENT SUPPORT
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Errata
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Illuminating the Hidden: Standardizing Cardiac MIBG Imaging for Sympathetic Dysfunction
  • PET/CT Case Series: Unmasking the Mystery of Cardiac Sarcoidosis
  • Delivery Methods of Radiopharmaceuticals: Exploring Global Strategies to Minimize Occupational Radiation Exposure
Show more Continuing Education

Similar Articles

Keywords

  • amyloid imaging
  • PET
  • antiamyloid therapeutics
  • quantification
  • reimbursement
SNMMI

© 2025 SNMMI

Powered by HighWire